[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 4,691
Citations 0
Clinical Trials Update
May 22/29, 2018

Drug Slows Disability Progression in Multiple Sclerosis

JAMA. 2018;319(20):2069. doi:10.1001/jama.2018.6256

Siponimod, a sphingosine-1-phosphate modulator, consistently slowed disability in secondary progressive multiple sclerosis (MS), according to a phase 3 trial published in the Lancet.

The study included 1 645 patients with secondary progressive MS and moderate or advanced disability (3.0-6.5 on the Expanded Disability Status Scale; 55% needed help walking) who were randomly assigned (2:1) to receive 2 mg of oral siponimod once daily or to placebo for up to 3 years or until their disability had progressed.